Free Trial

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure logo
$31.50 -0.04 (-0.13%)
(As of 12/17/2024 ET)

AtriCure - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
8

Based on 8 Wall Street analysts who have issued ratings for AtriCure in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for ATRC.

Consensus Price Target

$42.00
33.33% Upside
According to the 8 analysts' twelve-month price targets for AtriCure, the average price target is $42.00. The highest price target for ATRC is $61.00, while the lowest price target for ATRC is $26.00. The average price target represents a forecasted upside of 33.33% from the current price of $31.50.
Get the Latest News and Ratings for ATRC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AtriCure and its competitors.

Sign Up

ATRC Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.00$43.11$42.44$60.13
Forecasted Upside33.33% Upside24.17% Upside47.33% Upside67.62% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ATRC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATRC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AtriCure Stock vs. The Competition

TypeAtriCureMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside33.33% Upside28,647.34% Upside12.02% Upside
News Sentiment Rating
Positive News

See Recent ATRC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024JPMorgan Chase & Co.
3 of 5 stars
 Reiterated RatingOverweight$40.00+26.82%
12/9/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$53.00 ➝ $61.00+79.31%
10/30/2024Oppenheimer
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$32.00 ➝ $36.00+0.59%
10/30/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$35.00 ➝ $40.00+11.23%
10/30/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$34.00 ➝ $40.00+35.92%
7/31/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$58.00 ➝ $53.00+141.35%
7/31/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$30.00 ➝ $26.00+9.15%
7/31/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$65.00 ➝ $40.00+81.82%
11/29/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$60.00+60.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:34 AM ET.


ATRC Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for AtriCure is $42.00, with a high forecast of $61.00 and a low forecast of $26.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.

According to analysts, AtriCure's stock has a predicted upside of 33.33% based on their 12-month stock forecasts.

AtriCure has been rated by research analysts at Canaccord Genuity Group, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, and UBS Group in the past 90 days.

Analysts like AtriCure more than other "medical" companies. The consensus rating for AtriCure is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ATRC compares to other companies.


This page (NASDAQ:ATRC) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners